Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP5773280B2 - Method for simultaneous lysis of mycobacteria and separation of its nucleic acids - Google Patents
[go: Go Back, main page]

JP5773280B2 - Method for simultaneous lysis of mycobacteria and separation of its nucleic acids - Google Patents

Method for simultaneous lysis of mycobacteria and separation of its nucleic acids Download PDF

Info

Publication number
JP5773280B2
JP5773280B2 JP2012520447A JP2012520447A JP5773280B2 JP 5773280 B2 JP5773280 B2 JP 5773280B2 JP 2012520447 A JP2012520447 A JP 2012520447A JP 2012520447 A JP2012520447 A JP 2012520447A JP 5773280 B2 JP5773280 B2 JP 5773280B2
Authority
JP
Japan
Prior art keywords
acid
fast
mixed solution
nucleic acid
lysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012520447A
Other languages
Japanese (ja)
Other versions
JPWO2011158815A1 (en
Inventor
圭一 氏内
圭一 氏内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP2012520447A priority Critical patent/JP5773280B2/en
Publication of JPWO2011158815A1 publication Critical patent/JPWO2011158815A1/en
Application granted granted Critical
Publication of JP5773280B2 publication Critical patent/JP5773280B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Description

本発明は、結核菌に代表される抗酸菌の溶菌とその核酸の分離を簡便な操作で同時に行う方法に関する。   The present invention relates to a method for simultaneously performing lysis of acid-fast bacteria typified by Mycobacterium tuberculosis and separation of nucleic acids thereof by a simple operation.

結核は、日本でも復活の兆しを見せている細菌性疾患であり、その診断方法の改良は、極めて重要である。結核の診断方法としては、近年、数週間もの時間のかかる培養検査に代わって、短時間で高精度の結果が得られる遺伝子検査が行われるようになっている。   Tuberculosis is a bacterial disease that is showing signs of rebirth in Japan, and improvement of its diagnostic method is extremely important. As a method for diagnosing tuberculosis, in recent years, a genetic test that can obtain highly accurate results in a short time has been carried out instead of a culture test that takes several weeks.

結核の遺伝子検査は、結核菌の遺伝子に特異的なプライマーを使用したPCRにより、喀痰試料中の結核菌の存在を同定することによって行われる。遺伝子検査を行うには、前処理として、試料中の検査対象の菌細胞を溶菌(破壊)し、次いでその核酸を分離することが必要である。   Tuberculosis genetic testing is performed by identifying the presence of M. tuberculosis in sputum samples by PCR using primers specific for the M. tuberculosis gene. In order to perform a genetic test, as a pretreatment, it is necessary to lyse (destroy) the bacterial cells to be tested in the sample and then to separate the nucleic acid.

しかし、結核菌に代表される抗酸菌は、ミコール酸の脂質層を含む強固な細胞壁を持つため、大腸菌などの一般的な細菌と比較して溶菌が困難である。   However, acid-fast bacteria typified by Mycobacterium tuberculosis have a strong cell wall containing a lipid layer of mycolic acid, and are therefore difficult to lyse compared to general bacteria such as Escherichia coli.

抗酸菌の一般的な溶菌方法としては、超音波を使用して物理的に菌細胞を破壊する方法(特許文献1参照)、フェノールを溶菌剤として使用して菌細胞を破壊する方法、60〜100℃に加熱することで抗酸菌を溶菌する方法(特許文献2参照)が挙げられる。   As a general lysis method of acid-fast bacteria, a method of physically destroying bacterial cells using ultrasonic waves (see Patent Document 1), a method of destroying bacterial cells using phenol as a lysis agent, 60 The method (refer patent document 2) of lysing acid-fast bacteria by heating to -100 degreeC is mentioned.

これらの従来公知の抗酸菌の溶菌方法は、費用がかかったり、操作が煩雑であったり、安全性に欠けたり、溶菌効率が低かったりするという問題を有し、いずれも満足できるものではなかった。また、これらの方法は抗酸菌の溶菌後に別途その核酸の分離操作を行うことを必要とするので、操作全体が煩雑であるという問題があった。   These conventionally known mycobacterial lysis methods are problematic in that they are expensive, complicated to operate, lack of safety, and have low lysis efficiency. It was. In addition, these methods require a separate operation for separating the nucleic acid after lysis of the acid-fast bacterium, so that the entire operation is complicated.

WO 2007/094506WO 2007/094506 特開平6−319527JP-A-6-319527

本発明は、かかる従来技術の現状に鑑み創案されたものであり、その目的は、簡便な操作で効率的に抗酸菌の溶菌とその核酸の分離を同時に行うことができる方法を提供することにある。   The present invention was devised in view of the current state of the prior art, and an object of the present invention is to provide a method capable of efficiently simultaneously lysing mycobacterial lysis and its nucleic acid with a simple operation. It is in.

本発明者は、上記目的を達成するために鋭意検討した結果、まず、抗酸菌をカオトロピック塩と接触させて菌の細胞壁を柔らかくした後、これを特定の細孔径の細孔構造連続体内を繰り返し通過させることにより、細胞壁が効率的に破壊され、抗酸菌の溶菌と核酸の分離を同時に行うことができることを見出し、本発明の完成に至った。   As a result of intensive studies to achieve the above-mentioned object, the present inventor first brought an acid-fast bacterium into contact with a chaotropic salt to soften the cell wall of the bacterium, and this was then passed through a pore structure continuum having a specific pore size. By repeatedly passing the cells, the cell wall was efficiently destroyed, and it was found that lysis of acid-fast bacteria and separation of nucleic acids could be performed simultaneously, and the present invention was completed.

本発明は、以下の(1)〜(6)の構成を有するものである。
(1)カオトロピック塩と抗酸菌を含む混合液を調製し、前記混合液の温度を35〜80℃にし、次に細孔径3070μmの細孔構造連続体を内部に溶着したチップを使用して前記混合液の吸引及び吐出を繰り返すことによって抗酸菌の溶菌とその核酸の分離を同時に行うことを特徴とする方法。
(2)混合液中のカオトロピック塩の濃度が2〜6Mであることを特徴とする(1)に記載の方法。
(3)混合液のpHが4.5〜6.5であることを特徴とする(1)または(2)に記載の方法。
(4)吸引及び吐出の繰り返しが3回以上であることを特徴とする(1)〜(3)のいずれか一項に記載の方法。
(5)混合液が0.1〜1.0Mの濃度の酢酸塩をさらに含むことを特徴とする(1)〜(4)のいずれか一項に記載の方法。
(6)混合液が0.05〜0.5Mの濃度のグッドの緩衝液をさらに含み、この緩衝液がpH4.5〜6.5に緩衝pH範囲を有することを特徴とする(1)〜(4)のいずれか一項に記載の方法。
The present invention has the following configurations (1) to (6).
(1) Prepare a mixed solution containing a chaotropic salt and acid-fast bacteria, bring the temperature of the mixed solution to 35 to 80 ° C., and then chip with a pore structure continuous body having a pore diameter of 30 to 70 μm welded inside A method characterized in that lysis of acid-fast bacteria and separation of nucleic acids thereof are simultaneously carried out by repeating suction and discharge of the mixed solution.
(2) The method according to (1), wherein the concentration of the chaotropic salt in the mixed solution is 2 to 6M.
(3) The method according to (1) or (2), wherein the pH of the mixed solution is 4.5 to 6.5.
(4) The method according to any one of (1) to (3) , wherein the suction and discharge are repeated three or more times.
(5) The method according to any one of (1) to (4) , wherein the mixed solution further contains acetate having a concentration of 0.1 to 1.0M.
(6) The mixed solution further includes a Good buffer solution having a concentration of 0.05 to 0.5 M, and the buffer solution has a buffer pH range of pH 4.5 to 6.5. The method according to any one of (4) .

本発明の方法は、特定の細孔径の細孔構造連続体を内部に溶着したチップ内に、カオトロピック塩で細胞壁が柔らかくなった抗酸菌を繰り返し通過させるようにしているので、抗酸菌の溶菌とその核酸の分離を同時に簡単に効率的に行うことができる。   In the method of the present invention, the acid-fast bacterium having a cell wall softened with a chaotropic salt is repeatedly passed through a chip in which a continuous pore structure having a specific pore size is welded. Lysis and its nucleic acid can be separated easily and efficiently at the same time.

本発明の方法で使用するチップの構造の一例の概略図である。It is the schematic of an example of the structure of the chip | tip used by the method of this invention.

以下、本発明の方法を詳細に説明する。
本発明の方法は、特定の細孔径の細孔構造連続体を内部に溶着したチップを使用してカオトロピック塩と抗酸菌を含む混合液の吸引及び吐出を繰り返すことによって抗酸菌の溶菌とその核酸の分離を同時に行うことを特徴とするものである。
Hereinafter, the method of the present invention will be described in detail.
The method of the present invention uses acid-resistant bacteria lysis by repeating suction and discharge of a mixed solution containing a chaotropic salt and acid-fast bacteria using a chip in which a pore structure continuous body having a specific pore size is welded. The nucleic acids are separated at the same time.

本発明の方法の溶菌対象となる抗酸菌としては、例えば、鳥型結核菌(Mycobacterium avium)、エム・イントラセルラレエ(M.intracellularae)、エム・ゴルドネエ(M.gordonae)、ヒト型結核菌(M.tuberculosis)、エム・カンサシイ(M.kansasii)、エム・フォルツイツム(M.fortuitum)、エム・ケロネエ(M.chelonae)、ウシ型結核菌(M.bovis)、エム・スクロフラセウム(M.scrofulaceum)、パラ結核菌(M.paratuberculosis)、チモテ菌(M.phlei)、エム・マリヌム(M.marinum)、エム・シミエー(M.simiae)、エム・スクロフラセウム(M.scrofulaceum)、エム・スズルガイ(M.szulgai)、らい菌(M.leprae)、エム・キセノピ(M.xenopi)、エム・ウルセランス(M.ulcerans)、鼠らい菌(M.lepraemurium)、エム・フラベセンス(M.flavescens)、エム・テレエ(M.terrae)、エム・ノンクロモジェニクム(M.nonchromogenicum)、エム・マルメンス(M.malmoense)、エム・アシアティクム(M.asiaticum)、エム・ヴァケエ(M.vaccae)、エム・ガストリ(M.gastri)、エム・トリビアル(M.triviale)、エム・ヘモフィラム(M.haemophilum)、エム・アフリカヌム(M.africanum)、エム・サーモレジスタブル(M.thermoresistable)及びスメグマ菌(M.smegmatis)を挙げることができる。   Examples of mycobacteria to be lysed by the method of the present invention include Mycobacterium avium, M. intracellularellae, M. gordonae, and M. tuberculosis. (M. tuberculosis), M. kansasii, M. fortuitum, M. chelonae, M. bovis, M. scroflace. ), M. paratuberculosis, M. phlei, M. marinum, M. simiae, M. scroflacem (M. scro) ulaceum, M. szulgai, M. leprae, M. xenopi, M. ulcerans, M. lepraemurium, M. flavesens (M. flavescens), M. terrae, M. nonchromogenicum, M. malmoense, M. asiaticum, M. vaquee (M) Vaccae), M. gastri, M. triviale, M. haemophilum, M. africanum, M. Mention may be made of M. thermoresistable and M. smegmatis.

本発明の方法で使用されるカオトロピック塩は、タンパク質などの分子構造を不安定化する性質を持つ化学物質であり、生化学の分野において核酸抽出の際に細胞を溶解させる溶菌剤として使用される物質である。カオトロピック塩としては、従来公知のいかなるものも使用することができ、例えば、グアニジン塩、イソチアン酸ナトリウム、ヨウ化ナトリウム、ヨウ化カリウム、尿素、臭化ナトリウム、臭化カリウム、臭化カルシウム、臭化アンモニウム、過塩素酸ナトリウム、チオシアン酸ナトリウム、チオシアン酸カリウム、アンモニウムイソチオシアネート、塩化ナトリウム、塩化カリウム、塩化アンモニウムであることができる。これらの中でも、細胞溶解性と核酸回収効率の点からグアニジン塩が好ましい。グアニジン塩としては、塩酸グアニジン、グアニジンチオシアン酸塩(チオシアン酸グアニジン)、グアニジン硫酸塩、イソチオシアン酸グアニジンが挙げられ、これらの中でも、溶菌効率の点から塩酸グアニジンまたはグアニジンチオシアン酸塩が好ましい。これらの塩は、単独で用いても複数組合わせて用いてもよい。   The chaotropic salt used in the method of the present invention is a chemical substance that has the property of destabilizing molecular structures such as proteins, and is used as a lysing agent for lysing cells during nucleic acid extraction in the field of biochemistry. It is a substance. Any conventionally known chaotropic salt can be used, such as guanidine salt, sodium isothiocyanate, sodium iodide, potassium iodide, urea, sodium bromide, potassium bromide, calcium bromide, bromide. It can be ammonium, sodium perchlorate, sodium thiocyanate, potassium thiocyanate, ammonium isothiocyanate, sodium chloride, potassium chloride, ammonium chloride. Among these, a guanidine salt is preferable in terms of cell solubility and nucleic acid recovery efficiency. Examples of the guanidine salt include guanidine hydrochloride, guanidine thiocyanate (guanidine thiocyanate), guanidine sulfate, and guanidine isothiocyanate. Among these, guanidine hydrochloride or guanidine thiocyanate is preferable from the viewpoint of lysis efficiency. These salts may be used alone or in combination.

抗酸菌とカオトロピック塩は両者を含む混合液の状態で使用され、カオトロピック塩と抗酸菌を水や緩衝液などの適当な溶媒に溶解することによって容易に混合液に調製することができる。例えばカオトロピック塩と緩衝剤を脱イオン水に溶解させ、これに抗酸菌を一定濃度に調製した菌液を添加することにより、混合液を調製することができる。   The acid-fast bacterium and the chaotropic salt are used in the form of a mixed solution containing both, and the mixture can be easily prepared by dissolving the chaotropic salt and the acid-fast bacterium in an appropriate solvent such as water or a buffer solution. For example, a mixed solution can be prepared by dissolving a chaotropic salt and a buffering agent in deionized water and adding a bacterial solution in which acid-fast bacteria are prepared at a constant concentration.

混合液中のカオトロピック塩の濃度は、2〜6M(mol/L)であることが好ましく、さらに好ましくは3〜5M(mol/L)である。混合液中のカオトロピック塩の濃度が上記下限未満では、抗酸菌細胞壁の溶解効率が低下するおそれがあり、また、上記上限を超えると、カオトロピック塩が析出するおそれがある。   The concentration of the chaotropic salt in the mixed solution is preferably 2 to 6 M (mol / L), more preferably 3 to 5 M (mol / L). If the concentration of the chaotropic salt in the mixed solution is less than the lower limit, the lysis efficiency of the acid-fast bacterium cell wall may be reduced, and if it exceeds the upper limit, the chaotropic salt may be precipitated.

混合液のpHは、4.5〜6.5であることが好ましく、さらに好ましくは5.0〜6.0である。混合液のpHが上記下限未満になるかまたは上記上限を超えると、核酸の分離効率が低下するおそれがある。   It is preferable that pH of a liquid mixture is 4.5-6.5, More preferably, it is 5.0-6.0. If the pH of the mixed solution is less than the above lower limit or exceeds the above upper limit, the nucleic acid separation efficiency may be lowered.

混合液のpHを上述の範囲に維持するためには、溶液に適当な緩衝剤を添加することが好ましい。かかる緩衝剤の一例として、酢酸塩を挙げることができる。酢酸塩の中でも、酢酸カリウム、酢酸ナトリウムなどの一価の金属の酢酸塩が特に効果的である。これらの酢酸塩の混合液中の濃度は、0.1〜1.0M(mol/L)であることが緩衝効果の点で好ましい。また、かかる緩衝剤の別の例として、MES(2−モルホリノエタンスルホン酸)、ACES(N−(2−アセトアミド)−2−アミノエタンスルホン酸)、PIPES(ピペラジン−1,4−ビス(2−エタンスルホン酸))などの酸性側に緩衝能を持つグッドの緩衝液を挙げることができる。これらのグッドの緩衝液の混合液中の濃度は、0.05〜0.5M(mol/L)であることが緩衝効果の点で好ましい。   In order to maintain the pH of the mixed solution in the above range, it is preferable to add an appropriate buffer to the solution. An example of such a buffering agent is acetate. Among the acetates, monovalent metal acetates such as potassium acetate and sodium acetate are particularly effective. The concentration of these acetates in the mixed solution is preferably 0.1 to 1.0 M (mol / L) from the viewpoint of the buffer effect. As another example of such a buffer, MES (2-morpholinoethanesulfonic acid), ACES (N- (2-acetamido) -2-aminoethanesulfonic acid), PIPES (piperazine-1,4-bis (2) -Good buffer solution having a buffer capacity on the acidic side, such as ethanesulfonic acid)). The concentration of these Good buffers in the mixed solution is preferably 0.05 to 0.5 M (mol / L) from the viewpoint of the buffering effect.

本発明の方法では、カオトロピック塩と抗酸菌を含む混合液をそのまま常温で使用することも可能であるが、特定の温度に加熱して使用することが好ましい。加熱温度は、35〜80℃であり、好ましくは40〜75℃である。加熱すると、カオトロピック塩の溶解効果が向上しやすいが、加熱温度が高すぎると、液の蒸発が増加し、カオトロピック塩の濃度変化が生じるおそれがある。また、細孔構造連続体への核酸の吸着能が低下するおそれがある。   In the method of the present invention, a mixed solution containing a chaotropic salt and acid-fast bacteria can be used as it is at room temperature, but it is preferable to use it after heating to a specific temperature. The heating temperature is 35 to 80 ° C, preferably 40 to 75 ° C. When heated, the dissolution effect of the chaotropic salt is likely to be improved, but if the heating temperature is too high, the evaporation of the liquid increases and the concentration of the chaotropic salt may change. In addition, the nucleic acid adsorption ability to the pore structure continuum may be reduced.

加熱方法としては、特に限定されないが、混合液を適当なチューブに入れ、ヒートブロック、ウォーターバス、マイクロウェーブオーブン、エアーバス等の公知の加熱手段で加熱する方法が挙げられる。抗酸菌は、最初から混合液に添加しておいてもよいし、混合液が所定の温度に加熱されてから添加してもよい。   Although it does not specifically limit as a heating method, The method of putting a liquid mixture in a suitable tube and heating with well-known heating means, such as a heat block, a water bath, a microwave oven, an air bath, is mentioned. The acid-fast bacterium may be added to the mixed solution from the beginning, or may be added after the mixed solution is heated to a predetermined temperature.

本発明の方法は、細孔径3070μmの細孔構造連続体を内部に溶着したチップを使用して上記の混合液を繰り返し吸引及び吐出することにより、抗酸菌と細孔構造連続体内の細孔が接触し、抗酸菌の溶菌だけでなく、その核酸の分離も同時に行うことを特徴とする。 In the method of the present invention, the acid-fast bacterium and the pore structure continuous body are obtained by repeatedly sucking and discharging the above mixed solution using a chip having a pore structure continuous body having a pore diameter of 30 to 70 μm welded therein. In addition to the lysis of acid-fast bacteria, the nucleic acids are separated at the same time.

本発明の方法で使用するチップの構造の一例の概略図を図1に示す。本発明で使用するチップ1は、基本的に従来公知の構成(例えば図1に示す細長い逆円錐形状の中空体)を有するが、その内部が先端部から一定の長さにわたって細孔構造連続体2を溶着していることを特徴とする。細孔構造連続体は、連続した細孔構造を有するものであり、その細孔径は3070μmである。細孔径が上記範囲から逸脱すると、抗酸菌の溶菌と核酸の分離を効果的に行うことができない。細孔構造体の材質は特に限定されないが、シリカが好ましい。そのような構造体は「モノリスシリカ」または「シリカモノリス」とも呼ばれている。モノリスシリカは、三次元ネットワーク状の骨格と細孔流路を一体化した構造を持ち、しかも合成の際にミクロサイズの貫通孔、及び骨格表面のナノサイズの細孔を制御することができる特性を有する。 A schematic diagram of an example of the structure of a chip used in the method of the present invention is shown in FIG. The chip 1 used in the present invention basically has a conventionally known structure (for example, an elongated inverted conical hollow body shown in FIG. 1), and the inside thereof has a pore structure continuous body over a certain length from the tip. 2 is welded. Pore structure continuum are those having a continuous pore structure, the pore size is 30 ~ 70 μ m. If the pore diameter deviates from the above range, acid-fast bacteria lysis and nucleic acid separation cannot be performed effectively. The material of the pore structure is not particularly limited, but silica is preferable. Such structures are also referred to as “monolithic silica” or “silica monolith”. Monolithic silica has a structure that integrates a three-dimensional network-like skeleton and pore channels, and can control micro-sized through-holes and nano-sized pores on the skeleton surface during synthesis. Have

細孔構造連続体は一般的にゾル−ゲル法で製造されることができ、例えば金属アルコキシドを部分的に加水分解して反応性モノマーを作り、このモノマーを重縮合してコロイド状オリゴマーを作ってゾルを生成し、さらに加水分解して重合と架橋を促進させ、三次元構造を作ってゲルを生成することにより製造されることができる。細孔構造連続体は、チップ内部に収納されるサイズに整形された後、例えば超音波を使用してチップ内部に溶着される。   The pore structure continuum can generally be produced by a sol-gel method, for example, a metal alkoxide is partially hydrolyzed to produce a reactive monomer, and this monomer is polycondensed to produce a colloidal oligomer. Can be produced by forming a sol, further hydrolyzing to promote polymerization and crosslinking, and forming a three-dimensional structure to form a gel. The pore structure continuous body is shaped into a size accommodated in the chip, and then welded to the chip using, for example, ultrasonic waves.

細孔構造連続体を内部に溶着したチップは、シリンジなどに装着されてカオトロピック塩と抗酸菌を含む混合液の吸引及び吐出を繰り返す。吸引及び吐出の繰り返し回数は3回以上が好ましい。3回未満では、抗酸菌の溶菌と核酸の分離を十分に果たすことができないおそれがある。繰り返し回数に上限はないが、最大20回程度すれば十分である。   The chip in which the pore structure continuous body is welded is attached to a syringe or the like and repeatedly sucks and discharges the mixed liquid containing the chaotropic salt and acid-fast bacteria. The number of repetitions of suction and discharge is preferably 3 times or more. If it is less than 3 times, there is a possibility that acid-fast lysis and nucleic acid cannot be sufficiently separated. There is no upper limit to the number of repetitions, but a maximum of about 20 is sufficient.

以下、本発明を実施例によりさらに具体的に説明するが、本発明は、これらの実施例に限定されるものではない。   EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

参考例1
(1)抗酸菌の準備
抗酸菌としては、ウシ型結核菌Mycobacterium bovis BCG株(以下、BCG株と略す)を使用した。BCG株を3%小川培地(日水製薬製)中で35℃で2週間培養した後、抗酸菌培養用の液体培地であるMycoBroth(極東製薬工業製)に接種し、37℃で6日間さらに培養した。分散性の高い菌液を得るため、培養後の液体培地を孔径5μmの親水性フィルターでろ過した後、濁度計でOD600を測定しながら、マクファーランド比濁法に従ってマクファーランド1の濃度に菌液を調整した。次に、液体培地中に既に遊離している核酸を除去するため、この菌液1.0mLを1.5mLのチューブに加え、遠心分離操作で菌体だけを沈殿させ、上清を取り除いて1.0mLのリン酸緩衝液で菌体を再懸濁させた。
Reference example 1
(1) Preparation of acid-fast bacterium As the acid-fast bacterium, the Mycobacterium bovis BCG strain (hereinafter abbreviated as BCG strain) was used. The BCG strain was cultured in 3% Ogawa medium (Nissui Pharmaceutical Co., Ltd.) at 35 ° C. for 2 weeks, then inoculated into MycoBroth (manufactured by Kyokuto Pharmaceutical Co., Ltd.), a liquid medium for acid-fast bacteria culture, and incubated at 37 ° C. for 6 days. Further culture was performed. In order to obtain a highly dispersible bacterial solution, the cultured liquid medium was filtered with a hydrophilic filter having a pore size of 5 μm, and then the concentration of McFarland 1 was measured according to the McFarland turbidimetric method while measuring OD600 with a turbidimeter. The bacterial solution was adjusted. Next, in order to remove nucleic acid that has already been released in the liquid medium, 1.0 mL of this bacterial solution is added to a 1.5 mL tube, and only bacterial cells are precipitated by centrifugation, and the supernatant is removed to remove 1 The cells were resuspended with 0.0 mL of phosphate buffer.

(2)カオトロピック塩の溶液の準備
カオトロピック塩としてのグアニジンチオシアン酸及び緩衝剤としての酢酸カリウムを脱イオン水に溶解させ、緩衝剤を含有するカオトロピック塩の溶液を調製した。
(2) Preparation of chaotropic salt solution Guanidine thiocyanic acid as a chaotropic salt and potassium acetate as a buffering agent were dissolved in deionized water to prepare a solution of a chaotropic salt containing a buffering agent.

(3)混合液の調製
(2)で調製したカオトロピック塩の溶液500μLに、(1)で準備したマクファーランド1の菌液をリン酸緩衝液で1000倍に希釈したものを混合した。混合液中のグアニジンチオシアン酸の濃度は、5Mであり、酢酸カリウムの濃度は、0.8Mであり、溶液のpHは5.5であった。
(3) Preparation of Mixed Solution To 500 μL of the chaotropic salt solution prepared in (2), a solution obtained by diluting the McFarland 1 bacterial solution prepared in (1) 1000 times with a phosphate buffer was mixed. The concentration of guanidine thiocyanic acid in the mixed solution was 5M, the concentration of potassium acetate was 0.8M, and the pH of the solution was 5.5.

(4)抗酸菌の溶菌及び核酸の分離抽出
次に、図1に記載のような細孔構造連続体を内部に溶着したチップを使用して、混合液中の抗酸菌の溶菌とその核酸の分離抽出を行った。具体的には市販の250μLチップ内に細孔構造連続体(モノリスシリカ、細孔径30μm、切断面積3.14平方mm、厚さ1mm)を溶着したものをテルモ製の1mLシリンジに装着し、混合液を100μL/秒の速度で10回吸引および吐出し、混合液中の抗酸菌を溶菌し、その核酸をチップ中の細孔構造連続体に吸着させた。混合液を完全に出し切った後に、洗浄液500μLの入ったチューブにチップを移動させ、洗浄液を100μL/秒の速度で3回吸引および吐出して洗浄した。この洗浄工程をもう一度繰り返した。最後に溶出液100μLの入ったチューブにチップを移動させ、溶出液を100μL/秒の速度で5回吸引および吐出して、チップ中の細孔構造連続体に吸着した抗酸菌の核酸を溶出した。溶出効率の低下を抑えるため、吸引および吐出の間は、チップ内の細孔構造連続体に空気が接触しないように注意した。なお、洗浄液としては、70%エタノール中の0.8M酢酸カリウム溶液を使用し、溶出液としては、10mM水酸化カリウム水溶液を使用した。
(4) Lysis of acid-fast bacteria and separation and extraction of nucleic acid Next, using a chip having a pore structure continuous body as shown in FIG. Nucleic acid was separated and extracted. Specifically, a porous structure continuous body (monolithic silica, pore diameter 30 μm, cut area 3.14 square mm, thickness 1 mm) welded to a commercially available 250 μL chip is attached to a Terumo 1 mL syringe and mixed. The solution was sucked and discharged 10 times at a rate of 100 μL / second, the acid-fast bacteria in the mixed solution were lysed, and the nucleic acid was adsorbed to the pore structure continuum in the chip. After the mixed solution was completely discharged, the tip was moved to a tube containing 500 μL of the cleaning solution, and the cleaning solution was sucked and discharged three times at a rate of 100 μL / second for cleaning. This washing process was repeated once more. Finally, the tip is moved to a tube containing 100 μL of eluate, and the eluate is sucked and discharged five times at a rate of 100 μL / sec to elute nucleic acid of acid-fast bacteria adsorbed on the pore structure continuum in the chip. did. In order to suppress a decrease in elution efficiency, care was taken so that air did not contact the continuous pore structure in the chip during suction and discharge. Note that a 0.8 M potassium acetate solution in 70% ethanol was used as the washing solution, and a 10 mM potassium hydroxide aqueous solution was used as the eluent.

(5)リアルタイムPCRによる、抗酸菌遺伝子の検出及び定量
次に、(4)で得た核酸溶出液を対象として、リアルタイムPCRにより抗酸菌遺伝子の検出及び定量を行った。PCRの試薬組成、並びにPCR条件は、以下に示す通りであった。
(5) Detection and quantification of acid-fast bacterium genes by real-time PCR Next, the acid-fast bacterium genes were detected and quantified by real-time PCR for the nucleic acid eluate obtained in (4). The PCR reagent composition and PCR conditions were as shown below.

試薬組成:
オリゴ1 250nM、
オリゴ2 1500nM、
オリゴ3(5’末端をBODIPY−FL標識されている)250nM、
×10緩衝液 1μL、
dNTP 0.2mM、
MgSO 4mM、
KOD plus DNAポリメラーゼ 0.2U、
溶出液 1μL
(ミリQ水で全量を10μLに調整する)
(オリゴ1〜オリゴ3の配列は、配列表の配列番号1〜3に示される通りである。)
Reagent composition:
Oligo 1 250 nM,
Oligo 2 1500 nM,
Oligo 3 (5 ′ end labeled BODIPY-FL) 250 nM,
× 10 buffer 1 μL,
dNTP 0.2 mM,
MgSO 4 4 mM,
KOD plus DNA polymerase 0.2U,
Eluate 1μL
(Adjust the total volume to 10 μL with Milli-Q water)
(The sequences of oligo 1 to oligo 3 are as shown in SEQ ID NOs: 1 to 3 in the sequence listing.)

PCR条件:
熱変性:94℃・2分、98℃・0秒、アニーリング:60℃・5秒(蛍光検出)、50サイクル
PCR conditions:
Thermal denaturation: 94 ° C for 2 minutes, 98 ° C for 0 seconds, annealing: 60 ° C for 5 seconds (fluorescence detection), 50 cycles

上記試薬組成は、BCG株を特異的に検出できるプライマーとプローブの組み合わせである。陽性コントロールとして、BCG株からフェノール・クロロホルム法で抽出したゲノムDNAを10mMトリス緩衝液で1μL中に1000コピー含むように希釈したものを使用した。リアルタイムPCRは、増幅産物とプローブがハイブリダイゼーションするとプローブに標識された蛍光色素の蛍光が消光することに基づいてサンプル中の特定の核酸配列を検出するものである。核酸の増幅及び検出には、ロシュ・ダイアグノスティック社製ライトサイクラー(登録商標)を使用した。測定モードは、530nmを利用し、得られたリアルタイム検出データを利用して、アニーリング時のQProbe消光率を算出した。さらに、消光率2%に達したサイクル数を求めて、SYBR Green Iを用いたリアルタイム定量PCR法と同様にして解析を行った。抗酸菌の核酸の回収効率は、陽性コントロールを100%としてそれに対する百分率で表示した。なお、抗酸菌の核酸の回収効率は、30%以上であれば良好と考えられる。結果を表1に示す。   The reagent composition is a combination of a primer and a probe that can specifically detect the BCG strain. As a positive control, genomic DNA extracted from the BCG strain by the phenol / chloroform method was diluted with 10 mM Tris buffer so as to contain 1000 copies in 1 μL. Real-time PCR detects a specific nucleic acid sequence in a sample based on the fact that the fluorescence of the fluorescent dye labeled on the probe is quenched when the amplification product and the probe are hybridized. A light cycler (registered trademark) manufactured by Roche Diagnostics was used for amplification and detection of nucleic acid. As the measurement mode, 530 nm was used, and the obtained QProbe extinction ratio was calculated using the obtained real-time detection data. Furthermore, the number of cycles that reached a quenching rate of 2% was determined and analyzed in the same manner as the real-time quantitative PCR method using SYBR Green I. The nucleic acid recovery efficiency of acid-fast bacteria was expressed as a percentage relative to 100% positive control. In addition, it is considered that the nucleic acid recovery efficiency of acid-fast bacteria is good if it is 30% or more. The results are shown in Table 1.

実施例2
(3)で得た混合液を1.5mLのスクリュー付蓋のあるチューブに入れ、ヒートブロック上で65℃で5分間加熱したものを使用して(4)で吸引及び吐出を行った以外は、参考例1と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 2
The mixture obtained in (3) was put into a 1.5 mL tube with a screw cap and heated and heated at 65 ° C. for 5 minutes on a heat block, except that suction and discharge were performed in (4). In the same manner as in Reference Example 1, the recovery efficiency of acid-fast bacterium nucleic acids was displayed. The results are shown in Table 1.

参考例3
(4)の細孔構造連続体の細孔径を10μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Reference example 3
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum of (4) was changed to 10 μm. The results are shown in Table 1.

参考例4
(4)の細孔構造連続体の細孔径を20μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Reference example 4
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 20 μm. The results are shown in Table 1.

実施例5
(4)の細孔構造連続体の細孔径を40μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 5
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 40 μm. The results are shown in Table 1.

実施例6
(4)の細孔構造連続体の細孔径を50μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 6
The nucleic acid recovery efficiency of acid-fast bacteria was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuous body of (4) was changed to 50 μm. The results are shown in Table 1.

実施例7
(4)の細孔構造連続体の細孔径を70μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 7
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 70 μm. The results are shown in Table 1.

実施例8
カオトロピック塩としてグアニジンチオシアン酸の代わりに塩酸グアニジンを使用した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 8
The efficiency of acid-fast bacilli nucleic acid recovery was displayed in the same manner as in Example 2, except that guanidine hydrochloride was used in place of guanidine thiocyanate as the chaotropic salt. The results are shown in Table 1.

実施例9
抗酸菌の溶菌及びその核酸の分離の工程での吸引・吐出回数を5回に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 9
The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the number of suction / discharge in the process of lysis of the acid-fast bacterium and the separation of the nucleic acid was changed to 5. The results are shown in Table 1.

実施例10
抗酸菌の溶菌及びその核酸の分離の工程での吸引・吐出回数を20回に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 10
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the number of suction / discharge in the acid-fast bacilli lysis and nucleic acid separation steps was changed to 20. The results are shown in Table 1.

実施例11
加熱温度を40℃に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 11
The recovery efficiency of the acid-fast bacterium nucleic acid was displayed in the same manner as in Example 2 except that the heating temperature was changed to 40 ° C. The results are shown in Table 1.

実施例12
加熱温度を75℃に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 12
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the heating temperature was changed to 75 ° C. The results are shown in Table 1.

参考例13
加熱温度を95℃に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Reference Example 13
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the heating temperature was changed to 95 ° C. The results are shown in Table 1.

比較例1
(4)の細孔構造連続体の細孔径を120μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 1
The nucleic acid recovery efficiency of acid-fast bacteria was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuous body of (4) was changed to 120 μm. The results are shown in Table 1.

比較例2
(4)の細孔構造連続体の細孔径を5μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 2
The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the pore diameter of the continuous pore structure (4) was changed to 5 μm. The results are shown in Table 1.

比較例3
(2)のカオトロピック塩の溶液の代わりにミリQ水を使用した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 3
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that milliQ water was used instead of the chaotropic salt solution of (2). The results are shown in Table 1.

比較例4
抗酸菌の溶菌及びその核酸の分離の工程での吸引・吐出回数を1回に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 4
The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the number of suction / discharge in the acid-fast bacterium lysis and nucleic acid separation step was changed to 1. The results are shown in Table 1.

Figure 0005773280
Figure 0005773280

表1から、特定の細孔径の細孔構造連続体を内部に溶着したチップを使用して、特定の混合液の温度で吸引及び吐出を繰り返した実施例2及び512では、本発明の細孔径の範囲外の細孔構造連続体で処理された比較例1及び2、カオトロピック塩の溶液を使用しなかった比較例3、並びに吸引及び吐出を繰り返さなかった比較例4と比較して、核酸の回収効率が顕著に高いことが理解できる。 From Table 1, Examples 2 and 5 to 12 in which suction and discharge were repeated at a specific mixed liquid temperature using a chip in which a pore structure continuous body having a specific pore diameter was welded, were used in the present invention. Compared with Comparative Examples 1 and 2 treated with a pore structure continuum outside the range of pore diameter, Comparative Example 3 in which no chaotropic salt solution was used, and Comparative Example 4 in which suction and discharge were not repeated, It can be understood that the nucleic acid recovery efficiency is remarkably high.

本発明の方法は、強固な細胞壁のために溶菌が困難であった抗酸菌の溶菌とその核酸の分離を同時に効率良く、しかも簡便な操作で低コストかつ安全に行うことができるので、結核菌の遺伝子検査の前処理などに極めて有用である。   Since the method of the present invention can efficiently perform lysis of mycobacteria and its nucleic acid, which were difficult to lyse due to a strong cell wall, simultaneously and at low cost and safely by a simple operation, tuberculosis This is extremely useful for pretreatment of genetic testing of bacteria.

配列番号1は、実施例でオリゴ1として記載した設計されたポリヌクレオチドの配列である。
配列番号2は、実施例でオリゴ2として記載した設計されたポリヌクレオチドの配列である。
配列番号3は、実施例でオリゴ3として記載した設計されたポリヌクレオチドの配列である。
SEQ ID NO: 1 is the designed polynucleotide sequence described as Oligo 1 in the Examples.
SEQ ID NO: 2 is the designed polynucleotide sequence described as Oligo 2 in the Examples.
SEQ ID NO: 3 is the sequence of the designed polynucleotide described as Oligo 3 in the Examples.

Claims (6)

カオトロピック塩と抗酸菌を含む混合液を調製し、前記混合液の温度を35〜80℃にし、次に細孔径3070μmの細孔構造連続体を内部に溶着したチップを使用して前記混合液の吸引及び吐出を繰り返すことによって抗酸菌の溶菌とその核酸の分離を同時に行うことを特徴とする方法。 A mixture containing a chaotropic salt and acid-fast bacilli was prepared, the temperature of the mixture was 35 to 80 ° C., and then a chip having a pore structure continuous body having a pore diameter of 30 to 70 μm was used. A method comprising simultaneously lysing acid-fast bacteria and separating nucleic acids by repeating suction and discharge of the mixed solution. 混合液中のカオトロピック塩の濃度が2〜6Mであることを特徴とする請求項1に記載の方法。   The method according to claim 1, wherein the concentration of the chaotropic salt in the mixed solution is 2 to 6M. 混合液のpHが4.5〜6.5であることを特徴とする請求項1または2に記載の方法。   The method according to claim 1 or 2, wherein the pH of the mixed solution is 4.5 to 6.5. 吸引及び吐出の繰り返しが3回以上であることを特徴とする請求項1〜のいずれか一項に記載の方法。 The method according to any one of claims 1 to 3, wherein the repetition of the suction and discharge is not less than 3 times. 混合液が0.1〜1.0Mの濃度の酢酸塩をさらに含むことを特徴とする請求項1〜のいずれか一項に記載の方法。 The method according to any one of claims 1 to 4 , wherein the mixed solution further contains acetate having a concentration of 0.1 to 1.0M. 混合液が0.05〜0.5Mの濃度のグッドの緩衝液をさらに含み、この緩衝液がpH4.5〜6.5に緩衝pH範囲を有することを特徴とする請求項1〜のいずれか一項に記載の方法。 Any mixture further comprises a Good's buffer at a concentration of 0.05-0.5 M, according to claim 1-4 in which the buffer is characterized by having a buffered pH range pH4.5~6.5 The method according to claim 1.
JP2012520447A 2010-06-18 2011-06-14 Method for simultaneous lysis of mycobacteria and separation of its nucleic acids Active JP5773280B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012520447A JP5773280B2 (en) 2010-06-18 2011-06-14 Method for simultaneous lysis of mycobacteria and separation of its nucleic acids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010139368 2010-06-18
JP2010139368 2010-06-18
PCT/JP2011/063555 WO2011158815A1 (en) 2010-06-18 2011-06-14 Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium
JP2012520447A JP5773280B2 (en) 2010-06-18 2011-06-14 Method for simultaneous lysis of mycobacteria and separation of its nucleic acids

Publications (2)

Publication Number Publication Date
JPWO2011158815A1 JPWO2011158815A1 (en) 2013-08-19
JP5773280B2 true JP5773280B2 (en) 2015-09-02

Family

ID=45348214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520447A Active JP5773280B2 (en) 2010-06-18 2011-06-14 Method for simultaneous lysis of mycobacteria and separation of its nucleic acids

Country Status (3)

Country Link
JP (1) JP5773280B2 (en)
CN (1) CN102947449A (en)
WO (1) WO2011158815A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06319527A (en) * 1991-12-18 1994-11-22 Becton Dickinson & Co Method for lysing mycobacteria
WO2002078846A1 (en) * 2001-03-28 2002-10-10 Hitachi, Ltd. Instrument and method for collecting nucleic acids
JP2007306867A (en) * 2006-05-19 2007-11-29 Hitachi High-Technologies Corp Nucleic acid extraction apparatus and nucleic acid extraction method
WO2009058432A1 (en) * 2007-10-31 2009-05-07 Akonni Biosystems Sample preparation device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11266864A (en) * 1998-03-19 1999-10-05 Hitachi Ltd Method and apparatus for purifying nucleic acid
EP1719816B1 (en) * 2004-02-12 2011-06-01 GL Sciences Incorporated Mechanism of separating and purifying dna
JP4090443B2 (en) * 2004-02-24 2008-05-28 株式会社日立ハイテクノロジーズ Nucleic acid recovery instrument, its parts, and method of producing nucleic acid recovery instrument
JP4791750B2 (en) * 2005-04-15 2011-10-12 ジーエルサイエンス株式会社 Separation and purification method and separation and purification mechanism for DNA, etc.
JP5568968B2 (en) * 2009-11-30 2014-08-13 東洋紡株式会社 Lysing method of acid-fast bacterium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06319527A (en) * 1991-12-18 1994-11-22 Becton Dickinson & Co Method for lysing mycobacteria
WO2002078846A1 (en) * 2001-03-28 2002-10-10 Hitachi, Ltd. Instrument and method for collecting nucleic acids
JP2007306867A (en) * 2006-05-19 2007-11-29 Hitachi High-Technologies Corp Nucleic acid extraction apparatus and nucleic acid extraction method
WO2009058432A1 (en) * 2007-10-31 2009-05-07 Akonni Biosystems Sample preparation device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6011038841; J. Clin. Microbiol. Vol.31, No.4, 1993, pp.776-782 *
JPN6011038842; Appl. Environ. Microbiol. Vol.70, No.8, 2004, pp.4561-4568 *
JPN6015018074; J. Clin. Microbiol. Vol.28, No.3, 1990, pp.495-503 *

Also Published As

Publication number Publication date
JPWO2011158815A1 (en) 2013-08-19
CN102947449A (en) 2013-02-27
WO2011158815A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
Vandeventer et al. Mechanical disruption of lysis-resistant bacterial cells by use of a miniature, low-power, disposable device
JP6100162B2 (en) Universal lysis buffer and processing method for lysing body samples
WO2010086099A1 (en) Processing and analysis of viscous liquid biological samples
JP2625340B2 (en) Mycobacterial lysis method
EP2854981B1 (en) Methods of nucleic acid fractionation and detection
EP1574564B1 (en) Microorganism or cell collecting method, and microorganism or cell collecting implement used for the method
US12221647B2 (en) Methods for isolating microbial cells from a blood sample
CN103068979A (en) Solution for extraction of rna
CN111936633A (en) Microbial isolation and detection
JP2011509669A (en) Method for extracting and purifying nucleic acids on a membrane
EP3129498A1 (en) Nucleic acid purification method
JP6525001B2 (en) Method for recovering short strand nucleic acid
WO2016024263A1 (en) Methods for isolating microbial dna from a blood sample
JP5714291B2 (en) Extraction and purification of mycobacterial DNA
EP1730276B1 (en) Method, chip, device and system for extraction of biological materials
US20150152485A1 (en) Mycobacterium tuberculosis detection using transrenal dna
US20100280233A1 (en) Method for sample preparation
JP2004180551A (en) Method for collecting microorganism and method for amplifying or detecting gene using the same
JP5773280B2 (en) Method for simultaneous lysis of mycobacteria and separation of its nucleic acids
JP5568968B2 (en) Lysing method of acid-fast bacterium
JP2020130131A (en) Method for detecting microorganisms
JP6301260B2 (en) RNA preparation method
US10106837B1 (en) Processes for point of care detection of DNA and RNA
US20090142798A1 (en) Method of selectively lysing non-viable cells in cell population in sample
WO2024023523A1 (en) Methods for extraction and sequencing of nucleic acid

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150618

R151 Written notification of patent or utility model registration

Ref document number: 5773280

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250